Roche seeking earlier use for Lunsumio in FL on Phase III data
Roche is seeking a label expansion to use Lunsumio (mosunetuzumab) at an earlier stage after it showed benefit in a…
Oncology
-
-
J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC
Johnson & Johnson’s (J&J's) Rybrevant (amivantamab-vmjw) plus chemotherapy has been linked to the longest median overall survival (OS) seen in…
-
Akeso and Summit’s ivonescimab meets OS goals in NSCLC
Akeso and Summit Therapeutics’ ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study,…
-
Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter…
-
Surveillance and vaccine could protect against higher cancer risk from Lynch syndrome
In addition to cancer risk factors such as ageing, environmental risk factors, and lifestyle risk factors, family history of cancer…
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
-
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
On 17 August, AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy in first-line metastatic non-small…
-
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
AstraZeneca has ended a Phase III trial of its bispecific volrustomig pitted against MSD’s blockbuster Keytruda (pembrolizumab) in non-small cell…
-
UK Prime Minister to meet with brain cancer patient after research appeal
The UK's Prime Minister, Andy Burnham, has agreed to meet with a Team GB swimmer who suffers from brain cancer…
-
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Artificial intelligence (AI) was a hot topic on the agenda at the American Society of Clinical Oncology (ASCO) meeting 2026,…
